Natco Pharma’s Performance Analyzed
Natco Pharma’s stock price dropped slightly after news of an inspection by the U.S. Food and Drug Administration (USFDA). The inspection, conducted between November 17th and 21st, 2025, at Natco’s manufacturing plant in Manali, Chennai, resulted in seven observations. This means the USFDA found some issues that need to be fixed.
Key Points
- USFDA found seven issues during Natco’s Manali inspection.
- The inspection occurred between November 17th and 21st, 2025.
- Observations are primarily procedural and require corrective action.
- Natco is dedicated to following strict quality standards (cGMP).
- Stock price decreased, reflecting market reaction to concerns.
- Company’s profit and revenue saw slight declines in Q2 FY26.
Natco Pharma is a company based in Hyderabad, India, that makes medicines. They create both common (generic) and special medicines. They also make the ingredients that go into those medicines, and even products for farming.
Recently, the company’s overall profit was down 23.5% to Rs 518.40 crore. This is a decrease compared to the previous quarter. Revenue also dropped slightly to Rs 1,363 crore.
This situation highlights the importance of ongoing compliance and quality control within pharmaceutical manufacturing.
